Celcuity Inc. (NASDAQ:CELC) Short Interest Update

Celcuity Inc. (NASDAQ:CELC) saw a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 2,290,000 shares, a decline of 8.0% from the August 15th total of 2,490,000 shares. Based on an average trading volume of 370,300 shares, the short-interest ratio is presently 6.2 days.

Celcuity Price Performance

NASDAQ:CELC traded up $0.03 on Wednesday, hitting $15.01. The company had a trading volume of 213,726 shares, compared to its average volume of 282,679. Celcuity has a 52 week low of $8.39 and a 52 week high of $22.19. The company has a current ratio of 14.95, a quick ratio of 14.95 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $526.87 million, a price-to-earnings ratio of -5.39 and a beta of 0.76. The firm has a 50 day moving average of $16.79 and a two-hundred day moving average of $16.95.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09. During the same period in the prior year, the business posted ($0.66) EPS. On average, research analysts anticipate that Celcuity will post -2.54 earnings per share for the current year.

Hedge Funds Weigh In On Celcuity

Hedge funds have recently made changes to their positions in the stock. Quest Partners LLC increased its position in Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after purchasing an additional 1,379 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Celcuity by 78.5% in the 1st quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock valued at $193,000 after purchasing an additional 3,930 shares during the last quarter. Pale Fire Capital SE increased its position in shares of Celcuity by 38.4% during the fourth quarter. Pale Fire Capital SE now owns 14,409 shares of the company’s stock worth $210,000 after buying an additional 4,000 shares during the period. Commonwealth Equity Services LLC raised its stake in Celcuity by 9.9% during the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock worth $272,000 after buying an additional 1,500 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in Celcuity by 7.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock valued at $361,000 after buying an additional 1,600 shares during the period. 63.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Stifel Nicolaus decreased their price objective on Celcuity from $40.00 to $39.00 and set a “buy” rating for the company in a research note on Thursday, August 15th. Lifesci Capital assumed coverage on Celcuity in a research report on Monday, August 26th. They set an “outperform” rating and a $27.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research report on Thursday, August 15th. Leerink Partnrs upgraded Celcuity to a “strong-buy” rating in a research note on Monday, July 22nd. Finally, Leerink Partners assumed coverage on shares of Celcuity in a research note on Monday, July 22nd. They set an “outperform” rating and a $29.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $28.67.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.